section name header

Pronunciation

lan-REE-o-tide

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: somatostatin analogues

Indications

REMS


Action

  • Acts as an analog of somatostatin, inhibiting growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly. Also inhibits secretion of variety of other hormones secreted throughout gastrointestinal tract, including motilin, gastric inhibitory peptide, pancreatic polypeptide, gastrin, and cholecystokinin, which could be fueling tumor growth.
Therapeutic effects:
  • Decreased levels of GH and IGF-1 in patients with acromegaly resulting in decreased manifestations of acromegaly.
  • Improve progression-free survival in patients with GEP-NETs.
  • need for short-acting somatostatin analog rescue therapy.

Pharmacokinetics

Absorption: Following SUBQ administration, lanreotide precipitates in body tissues acting as a depot formulation from which drug is slowly released (75% bioavailability).

Distribution: Unknown.

Metabolism/Excretion: Minimal renal/fecal excretion, some biliary excretion.

Half-Life: 23–30 days.

Time/Action Profile

ROUTEONSETPEAKDURATION
SUBQunknownfirst 24 hr1 mo





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: bradycardia, hypertension

Endo: hyperglycemia, hypoglycemia, hypothyroidism

GI: abdominal pain, cholelithiasis, diarrhea, abdominal bloating, cholecystitis, fat malabsorption, PANCREATITIS, steatorrhea, stool discoloration

Hemat: anemia

Local: injection site reactions

Metab: weight loss

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Acromegaly

GEP-NETs and Carcinoid Syndrome

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Somatuline Depot

Canadian Brand Names

Somatuline Autogel